Halozyme Therapeutics, Inc. (FRA:RV7)

Halozyme Therapeutics Statistics

Total Valuation

FRA:RV7 has a market cap or net worth of EUR 7.11 billion. The enterprise value is 8.84 billion.

Market Cap	7.11B
Enterprise Value	8.84B

Important Dates

The last earnings date was Tuesday, February 17, 2026.

Earnings Date	Feb 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	118.02M
Shares Outstanding	n/a
Shares Change (YoY)	-4.27%
Shares Change (QoQ)	-3.81%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	116.55M

Valuation Ratios

The trailing PE ratio is 26.34 and the forward PE ratio is 8.75.

PE Ratio	26.34
Forward PE	8.75
PS Ratio	5.98
PB Ratio	171.02
P/TBV Ratio	n/a
P/FCF Ratio	12.95
P/OCF Ratio	12.81
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.48, with an EV/FCF ratio of 16.10.

EV / Earnings	32.74
EV / Sales	7.45
EV / EBITDA	11.48
EV / EBIT	12.75
EV / FCF	16.10

Financial Position

The company has a current ratio of 4.66, with a Debt / Equity ratio of 44.60.

Current Ratio	4.66
Quick Ratio	3.30
Debt / Equity	44.60
Debt / EBITDA	2.40
Debt / FCF	3.38
Interest Coverage	45.03

Financial Efficiency

Return on equity (ROE) is 153.59% and return on invested capital (ROIC) is 32.36%.

Return on Equity (ROE)	153.59%
Return on Assets (ROA)	22.24%
Return on Invested Capital (ROIC)	32.36%
Return on Capital Employed (ROCE)	34.76%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	2.81M
Profits Per Employee	638,048
Employee Count	423
Asset Turnover	0.61
Inventory Turnover	1.95

Taxes

In the past 12 months, FRA:RV7 has paid 127.74 million in taxes.

Income Tax	127.74M
Effective Tax Rate	32.13%

Stock Price Statistics

The stock price has increased by +9.48% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+9.48%
50-Day Moving Average	60.56
200-Day Moving Average	56.26
Relative Strength Index (RSI)	44.59
Average Volume (20 Days)	135

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.22

Income Statement

In the last 12 months, FRA:RV7 had revenue of EUR 1.19 billion and earned 269.89 million in profits. Earnings per share was 2.18.

Revenue	1.19B
Gross Profit	925.24M
Operating Income	695.24M
Pretax Income	397.64M
Net Income	269.89M
EBITDA	764.69M
EBIT	695.24M
Earnings Per Share (EPS)	2.18

Balance Sheet

The company has 121.64 million in cash and 1.85 billion in debt, with a net cash position of -1.73 billion.

Cash & Cash Equivalents	121.64M
Total Debt	1.85B
Net Cash	-1.73B
Net Cash Per Share	n/a
Equity (Book Value)	41.57M
Book Value Per Share	0.35
Working Capital	552.00M

Cash Flow

In the last 12 months, operating cash flow was 554.93 million and capital expenditures -5.94 million, giving a free cash flow of 549.00 million.

Operating Cash Flow	554.93M
Capital Expenditures	-5.94M
Free Cash Flow	549.00M
FCF Per Share	n/a

Margins

Gross margin is 77.78%, with operating and profit margins of 58.45% and 22.69%.

Gross Margin	77.78%
Operating Margin	58.45%
Pretax Margin	33.43%
Profit Margin	22.69%
EBITDA Margin	64.29%
EBIT Margin	58.45%
FCF Margin	46.15%

Dividends & Yields

FRA:RV7 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	4.27%
Shareholder Yield	4.27%
Earnings Yield	3.80%
FCF Yield	7.72%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:RV7 has an Altman Z-Score of 3.78 and a Piotroski F-Score of 6.

Altman Z-Score	3.78
Piotroski F-Score	6